Brief: Nanobiotix Announces Publication Of New Preclinical Immunotherapy Data

Nanobiotix SA

27/01/2022 07:44

Jan 27 (Reuters) - NANOBIOTIX SA  NANOB.PA :
    * NANOBIOTIX ANNOUNCED ON WEDNESDAY PUBLICATION OF NEW
PRECLINICAL
IMMUNOTHERAPY DATA SHOWCASING THE COMBINATION POTENTIAL OF
NBTXR3 WITH ANTI-PD-1 AND ANTI-CTLA-4
    * DATA SUGGEST THAT THE POTENTIAL IMMUNE PRIMING EFFECT OF
NBTXR3
MAY SCALE BEYOND ANTI-PD-1, AND COULD MERIT FURTHER
INVESTIGATION IN PRECLINICAL AND CLINICAL SETTINGS    

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nNDL69ty63
 Further company coverage:  NANOB.PA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))